Skip to content

US · ESLA · BIOTECHNOLOGY

Estrella Immunopharma, Inc. (ESLA) intrinsic value and stock valuation

$0.32as of 2026-11-21 · Mkt cap 30.83M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Estrella Immunopharma, Inc. DCF and intrinsic value

InvestorsCraft values ESLA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ESLA’s statements →

Estrella Immunopharma, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology EmeryVille, CA 94608 estrellabio.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$0.00
20212025
Net income
-$-13.06M
20212025
Free cash flow
-$-1.79M
20212025
Total equity
-$-10.37M
20222025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
2025202420222021
Revenue$0.00$0.00$0.00$0.00
Operating income-$-13.06M-$-8.85M-$-1.57M-$-730K
Net income-$-13.06M-$-8.85M-$-1M-$-730K
EPSd-$-354.7K-$-241.28K-$-173.61K-$-20.74K
Operating cash flow-$-1.79M-$-7.64M-$-1.04M-$-670K
Capital expenditure$0.00-$0.00$0.00$0.00
Free cash flow-$-1.79M-$-7.64M-$-1.04M-$-670K
Total assets$3.18M$3.14M$9.99M—
Total debt$0.00$0.00$500K—
Net debt-$-1.38M-$-920K$460K—
Total equity-$-10.37M$140K$7.07M—
Cash and short-term investments$1.38M$920K$40K—
Income statement
2025202420222021
Revenue$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00
Research and development expenses$10.3M$6.41M$10.5M$460K
Selling, general and administrative expenses$2.81M$2.44M$1.37M$280K
Other expenses$0.00$0.00$200K$0.00
Operating expenses$13.1M$8.85M$1.57M$730K
Cost and expenses$13.1M$8.85M$1.57M$730K
Interest income$0.00$0.00$650K$0.00
Interest expense$0.00$0.00$0.00$0.00
Depreciation and amortization$0.00$0.00$230K$210K
Ebitda-$-13.06M-$-8.85M-$-690K-$-730K
Operating income-$-13.06M-$-8.85M-$-1.57M-$-730K
Total other income/expenses, net$0.00$0.00$650K$0.00
Income before tax-$-13.06M-$-8.85M-$-920K-$-730K
Income tax expense$0.00$0.00$80K$0.00
Net income-$-13.06M-$-8.85M-$-1M-$-730K
Weighted average shares outstanding$36.8M$36.7M$5.76M$35.2M
Weighted average diluted shares outstanding$36.8M$36.7M$5.76M$35.2M
Balance sheet
202520242022
Cash and short-term investments$1.38M$920K$40K
Net receivables$0.00$0.00$0.00
Inventory$0.00$0.00$0.00
Total current assets$1.68M$1.64M$50K
Property, plant and equipment, net$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00
Long-term investments$0.00$0.00$9.67M
Total non-current assets$1.5M$1.5M$9.93M
Total assets$3.18M$3.14M$9.99M
Accounts payable$550K$0.00$50K
Short-term debt$0.00$0.00$500K
Deferred revenue$0.00$0.00$0.00
Total current liabilities$13.5M$3M$1.07M
Long-term debt$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$1.84M
Capital lease obligations$0.00$0.00$0.00
Total liabilities$13.5M$3M$2.92M
Common stock$0.00$0.00$9.33M
Retained earnings-$-36.99M-$-23.93M-$-2.26M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00
Total equity-$-10.37M$140K$7.07M
Total investments$0.00$0.00$9.67M
Total debt$0.00$0.00$500K
Net debt-$-1.38M-$-920K$460K
Cash flow statement
2025202420222021
Net income-$-13.06M-$-8.85M-$-1M-$-730K
Depreciation and amortization$0.00$0.00$0.00$0.00
Stock-based compensation$0.00$0.00$0.00$60K
Change in working capital$10.6M$780K$580K$0.00
Accounts receivable$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Accounts payable$550K-$-70K$0.00$0.00
Net cash provided by operating activities-$-1.79M-$-7.64M-$-1.04M-$-670K
Investments in property, plant and equipment$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$36.2M$0.00
Common stock issued$2.4M$80K$0.00$0.00
Common stock repurchased-$-30K-$-570K-$-36.11M$0.00
Dividends paid$0.00$0.00$0.00$0.00
Net cash used for financing activities$2.25M-$-490K-$-35.56M$670K
Net change in cash$470K-$-8.13M-$-440K$0.00
Cash at end of period$1.38M$920K$40K$0.00
Operating cash flow-$-1.79M-$-7.64M-$-1.04M-$-670K
Capital expenditure$0.00-$0.00$0.00$0.00
Free cash flow-$-1.79M-$-7.64M-$-1.04M-$-670K
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Estrella Immunopharma, Inc.

        Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.

        CEO
        Cheng Liu
        Employees
        3
        Beta
        0.86

        Explore

        Frequently asked questions

        What is the intrinsic value of Estrella Immunopharma, Inc. (ESLA)?

        InvestorsCraft does not currently publish an intrinsic value for ESLA. How the IC value is calculated.

        Is ESLA undervalued?

        InvestorsCraft does not publish an undervaluation signal for ESLA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.